Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Catalyst Pharm Inc
(NQ:
CPRX
)
14.72
-0.30 (-2.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Catalyst Pharm Inc
< Previous
1
2
3
4
5
6
Next >
Why the growth investor may take a look at NASDAQ:CPRX.
August 21, 2023
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) may be suited for growth investing, we'll explore why in this article.
Via
Chartmill
Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+
August 16, 2023
Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.
Via
Investor's Business Daily
ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold
August 15, 2023
One key metric to look for in a stock is an 80-plus Relative Strength Rating. ACELYRIN stock hit that mark on Tuesday, with a jump to 81.
Via
Investor's Business Daily
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
August 15, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Exelixis Stock Sees Rising Relative Strength Rating
August 14, 2023
On Monday, Exelixis stock hit an key technical milestone, with its Relative Strength Rating rising to 87, an increase from 79 the day before.
Via
Investor's Business Daily
5 Analysts Have This to Say About Catalyst Pharmaceuticals
August 11, 2023
Via
Benzinga
Where Catalyst Pharmaceuticals Stands With Analysts
July 21, 2023
Via
Benzinga
The Latest Analyst Ratings for Catalyst Pharmaceuticals
June 21, 2023
Via
Benzinga
Catalyst Pharmaceuticals: Q1 Earnings Insights
May 10, 2023
Via
Benzinga
1 Growth Stock to Buy Before the Next Bull Market
April 04, 2023
The stock is on a roll, and the company just made a major new purchase.
Via
The Motley Fool
7 ‘Strong Buy’ Value Stocks You Should Be Loading Up On Now
August 03, 2023
Although ultra-cheap ideas tend to carry significant risks, these strong buy value stocks offer the endorsement of analysts.
Via
InvestorPlace
7 Little-Known Stocks to Buy Now Before They Become the Next Big Thing
July 02, 2023
Although people might not readily recognize these little-known stocks, they offer surprisingly robust upside potential.
Via
InvestorPlace
ETF Returns: Mid-Cap Winners And Losers
June 28, 2023
We performed a screening of mid-cap ETFs - defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns on...
Via
Benzinga
Truist Securities Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
June 21, 2023
Via
Benzinga
The 7 Best Stocks Under $15 to Buy in June 2023
June 01, 2023
While you generally get what you pay for, these best stocks under $15 for June provide compelling opportunities at discount.
Via
InvestorPlace
Analyst Expectations for Catalyst Pharmaceuticals's Future
March 20, 2023
Via
Benzinga
4 Analysts Have This to Say About Catalyst Pharmaceuticals
March 20, 2023
Via
Benzinga
Catalyst Pharmaceuticals Earnings Perspective: Return On Capital Employed
March 16, 2023
Via
Benzinga
Down 19% in 1 Day, Is Catalyst Pharmaceuticals a Smart Contrarian Buy?
May 22, 2023
When evaluating investments, it helps to keep quarterly performance in context.
Via
The Motley Fool
Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
May 15, 2023
Ultragenyx Pharm shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 81.
Via
Investor's Business Daily
Market Rally Diverges; Google Surges On AI News, Inflation Cools, But Breadth Weak: Weekly Review
May 12, 2023
The Nasdaq hit a new 2023 high, but not the S&P 500 or Dow Jones.
Via
Investor's Business Daily
IBD 50 Leader And No. 1 Biotech Catalyst Puts Up 128% Earnings Growth
May 11, 2023
Though Catalyst's unadjusted earnings missed forecasts, they grew by triple digits.
Via
Investor's Business Daily
Earnings Outlook For Catalyst Pharmaceuticals
March 14, 2023
Via
Benzinga
Why Groupon Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 11, 2023
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 109.8% to $1.06 after reporting a rise in Q1 sales.
Via
Benzinga
7 A-Rated Stocks to Buy for April 2023
April 07, 2023
Now that the first quarter's in the bank, here are seven A-rated stocks to buy for April to keep your portfolio in top-notch shape.
Via
InvestorPlace
2 Top Growth Stocks That Can Withstand an Economic Downturn
April 05, 2023
These two drugmakers should march higher in 2023 and beyond.
Via
The Motley Fool
Why Catalyst Pharmaceuticals Shares Are Moving
March 16, 2023
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.
Via
Benzinga
Catalyst Pharma The No. 1 Biotech, Just Crushed 2023 Guidance Estimates
March 15, 2023
The guidance includes Catalyst's newest, and second, product.
Via
Investor's Business Daily
7 Core Stocks to Build a Solid Portfolio Around
March 13, 2023
You’ll enjoy your investing journey more if you know that you can rely on your core of stocks to buy to provide a solid foundation.
Via
InvestorPlace
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.